Processa Pharmaceuticals has acquired Vidya Therapeutics, a clinical-stage biotechnology company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated diseases. The product is initially focused on potentially best-in-class BTK inhibition in food allergy, chronic spontaneous urticaria (CSU) and relapsing multiple sclerosis (RMS). Concurrent with the acquisition, Processa entered into a definitive agreement for […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!